Why BioCryst Pharmaceuticals Stock Is Skyrocketing This Week
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) were skyrocketing 40.2% higher this week as of the market close on Thursday, according to on data from S&P Global Market Intelligence. The big gain came after the company provided an upbeat update on Monday.
BioCryst announced preliminary net revenue for hereditary angioedema (HAE) drug Orladeyo of $45.6 million for the fourth quarter of 2021. This figure brings the full-year 2021 sales for the drug to $122 million. The company also said it expects Orladeyo's sales in 2022 to more than double to at least $250 million. Peak sales of the HAE drug are anticipated to reach $1 billion.
In addition, BioCryst stated that it has begun enrolling patients in two pivotal clinical studies evaluating its experimental oral Factor D inhibitor, BCX990, in treating rare genetic disease paroxysmal nocturnal hemoglobinuria (PNH).
Source Fool.com
